August 28, 2014 6:24 AM ET


Company Overview of T2 Biosystems, Inc.

Company Overview

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products based on its proprietary platform. Its T2 Magnetic Resonance platform enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. The company offers T2Dx, a bench-top instrument, which has completed a pivotal clinical trial for performing diagnostic tests in sepsis and other applications; and T2Stat, an integrated instrument for hemostasis applications. It is also developing T2Candida panel that has completed a pivotal clinical trial for identifying pathogens associated with sepsis; T2HemoStat p...

101 Hartwell Avenue

Lexington, MA 02421

United States

Founded in 2006

61 Employees





Key Executives for T2 Biosystems, Inc.

Chief Executive Officer
Age: 54
Total Annual Compensation: $350.0K
Chief Financial Officer and Chief Accounting Officer
Age: 38
Total Annual Compensation: $171.9K
Chief Operating Officer
Age: 55
Total Annual Compensation: $89.8K
Compensation as of Fiscal Year 2013.

T2 Biosystems, Inc. Key Developments

T2 Biosystems, Inc.(NasdaqGM:TTOO) added to NASDAQ Composite Index

T2 Biosystems, Inc. will be added to the NASDAQ Composite Index.

T2 Biosystems Seeks Acquisitions

T2 Biosystems, Inc. has filed an IPO in the amount of $69.00 million. T2 Biosystems intends to use the net proceeds to fund research and development programs, to obtain marketing authorization from the FDA, and support the commercialization of, our T2Dx and T2Candida product candidates, including the hiring of additional sales, marketing and manufacturing personnel and related support costs associated with sales, marketing and manufacturing activities, and the balance for other general corporate purposes, including general and administrative expenses, working capital, capital expenditures to add equipment for laboratory and manufacturing-related purposes and to support expansion of facilities, and the repayment of indebtedness.

T2 Biosystems Submits 510(K) Application to the FDA for Review of T2Dx and T2Candida

T2 Biosystems announced that it has filed a 510(k) premarket submission for T2Dx and T2Candida with the U.S. Food and Drug Administration (FDA). The premarket submission includes clinical trial and other data providing evidence that the T2Dx instrument and the T2Candida test panel may identify specific life-threatening sepsis-causing pathogens directly from an unpurified blood sample as fast as three hours, rather than the two to five days typically required for blood culture-based diagnostics.

Similar Private Companies By Industry

Company Name Region
ProNAi Therapeutics, Inc. United States
AngioDesign Inc. United States
Seahawk Biosystems Corporation United States
BioPharm Solutions, Inc. United States
Bio Matrix United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact T2 Biosystems, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at